NeurAxis, Inc. announced the results of a multicenter registry study on IB-Stim for pediatric disorders of gut-brain interaction (DGBI). IB-Stim is NeurAxis? proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology therapy.

The large and comprehensive study concluded efficacy of IB-Stim for gastrointestinal symptoms and functionality for pediatric disorders of gut-brain interaction (DGBI). Seven large, tertiary care centers in the US enrolled patients undergoing treatment with IB-Stim. Overall, 292 patients met Rome IV Diagnostic criteria for any pain associated disorder of the gut-brain interactions.

In this cohort, 92% had failed medications therapy and 61% of patients had failed 4 or more medication when they entered the study. Patients were asked to fill out several validated pediatric measures, including the abdominal pain index (API), a validated questionnaire that assesses frequency, duration, and intensity of abdominal pain episodes. Data was collected weekly for the first 3 weeks and at 3, 6, 9 and 12 months.

Compared to baseline scores, there were significant improvements in the API after 4 weeks of IB-Stim treatment at every time point, including 6 month (p<0.001) and 12 months (p<0.001).